tetano
Editor, Senior Moderator
Expert Rev Respir Med. 2015 Nov 28. [Epub ahead of print]
[h=1]OSELTAMIVIR FOR INFLUENZA INFECTION IN CHILDREN: RISKS AND BENEFITS.[/h] Esposito S[SUP]1[/SUP], Principi N[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a common disease affecting many children each year. In a number of cases, particularly in children <2 years old and in those with severe chronic underlying disease, influenza can be complicated by lower respiratory tract infections, acute otitis media, rhinosinusitis, febrile seizures, dehydration or encephalopathy. Oseltamivir is the influenza virus drug that is most commonly studied in children for both the treatment and prevention of influenza. To avoid the risk that children with mild influenza or patients suffering from different viral infections receive oseltamivir, oseltamivir treatment should be recommended only in severe influenza cases, especially if confirmed by reliable laboratory tests. However, therapy must be initiated considering the risk of complications and the presence of severe clinical manifestations at age- and weight-appropriate doses. Because the vaccine remains the best option for preventing influenza and its complications, prophylaxis using oseltamivir should only be considered in select patients.
[h=4]KEYWORDS:[/h] antiviral prophylaxis; antiviral therapy; children; influenza; neuraminidase inhibitor; oseltamivir
PMID: 26616633 [PubMed - as supplied by publisher]
[h=1]OSELTAMIVIR FOR INFLUENZA INFECTION IN CHILDREN: RISKS AND BENEFITS.[/h] Esposito S[SUP]1[/SUP], Principi N[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a common disease affecting many children each year. In a number of cases, particularly in children <2 years old and in those with severe chronic underlying disease, influenza can be complicated by lower respiratory tract infections, acute otitis media, rhinosinusitis, febrile seizures, dehydration or encephalopathy. Oseltamivir is the influenza virus drug that is most commonly studied in children for both the treatment and prevention of influenza. To avoid the risk that children with mild influenza or patients suffering from different viral infections receive oseltamivir, oseltamivir treatment should be recommended only in severe influenza cases, especially if confirmed by reliable laboratory tests. However, therapy must be initiated considering the risk of complications and the presence of severe clinical manifestations at age- and weight-appropriate doses. Because the vaccine remains the best option for preventing influenza and its complications, prophylaxis using oseltamivir should only be considered in select patients.
[h=4]KEYWORDS:[/h] antiviral prophylaxis; antiviral therapy; children; influenza; neuraminidase inhibitor; oseltamivir
PMID: 26616633 [PubMed - as supplied by publisher]